Patent directory · USPTO A61K / A61P
Patents matching “adalimumab”
37 pharma patents match "adalimumab" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 37 pharmaceutical patents matching "adalimumab" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 12246064
Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
granted -
US 11229702
High concentration formulations of adalimumab
granted -
US 10799585
Stable aqueous formulations of adalimumab
granted -
US 10786566
Stable aqueous formulations of adalimumab
granted -
US 10780163
Stable aqueous formulations of adalimumab
granted -
US 10772960
Stable aqueous formulations of adalimumab
granted -
US 10772959
Stable aqueous formulations of adalimumab
granted -
US 10722579
Stable aqueous formulations of adalimumab
granted -
US 10716852
Stable aqueous formulations of adalimumab
granted -
US 10716853
Stable aqueous formulations of adalimumab
granted -
US 10716854
Stable aqueous formulations of adalimumab
granted -
US 10688183
Stable aqueous formulations of adalimumab
granted -
US 10286071
Syringe containing stable aqueous formulations of adalimumab
granted -
US 10286072
Methods of manufacturing stable aqueous formulations of adalimumab
granted -
US 10207000
Stable aqueous formulations of adalimumab
granted -
US 10195275
Stable aqueous formulations of adalimumab
granted -
US 10159732
Stable aqueous formulations of adalimumab
granted -
US 10159733
Stable aqueous formulations of adalimumab
granted -
US 10155039
Stable aqueous formulations of adalimumab
granted -
US 9861695
Stable aqueous formulations of adalimumab
granted -
US 9808525
Stable aqueous formulations of adalimumab
granted -
US 9789185
Stable aqueous formulations of adalimumab
granted -
US 9782480
Stable aqueous formulations of adalimumab
granted -
US 9782479
Stable aqueous formulations of adalimumab
granted